International Journal of Pharmaceutical and Bio-Medical Science

ISSN(print): 2767-827X, ISSN(online): 2767-830X

Volume 06 Issue 07 July 2026

Page No : 1138-1151

DOI: https://doi.org/10.47191/ijpbms/v6-i7-05, Impact Factor: 8.428

Recent Advances in Cancer Treatment Drugs: The Developmental Journey from Preclinical Discovery to Market Approval

Rokonuzzaman[1], MD Nazmul Islam[2]

[1]School of Pharmaceutical Engineering and Life Science, Changzhou University, Changzhou, Jiangsu, 213164, China

[2]School of Safety Science and Engineering, Changzhou University, Changzhou, Jiangsu 213164, China

ABSTRACT

The oncology landscape is undergoing a profound paradigm shift from broad-spectrum cytotoxic chemotherapies to highly selective, mechanism-driven precision medicine. This report systematically reviews the structural development, validation pathways, and regulatory mechanisms of next-generation oncology therapeutics. Modern precision oncology focuses on the targetable oncogenic drivers of malignant transformation—including epidermal growth factor receptor (EGFR) exon 20 insertions, human epidermal growth factor receptor 2 (HER2) mutations, Kirsten rat sarcoma virus oncogene (KRAS) G12C, and estrogen receptor 1 (ESR1) mutations—via small-molecule kinase inhibitors, antibody-drug conjugates (ADCs) featuring stable linkers and topoisomerase I payloads, and proteolysis-targeting chimeras (PROTACs). We highlight clinical milestones and regulatory approvals from 2025 and 2026, including the landmark PROTAC vepdegestrant, bispecific antibodies such as zenocutuzumab, and novel combinations like teclistamab with daratumumab.

Preclinical validation has evolved through three-dimensional patient-derived organoids (PDOs) and patient-derived xenograft (PDX) mouse models to characterize pharmacokinetic and pharmacodynamic profiles with high translational fidelity. In clinical phases, innovative dose-escalation strategies, such as accelerated titration and adaptive master protocols, including basket, umbrella, and platform designs, have accelerated efficacy evaluations. These designs are increasingly optimized through artificial intelligence (AI), utilizing machine learning for biomarker stratification, patient matching, and the generation of synthetic control arms. Finally, this review highlights the transition toward personalized oncology vaccines, such as mRNA-based intismeran autogene, and completely customized multi-targeted drug regimens. This synthesized analysis outlines how the convergence of structural biology, computational oncology, and flexible regulatory frameworks is fundamentally accelerating the transition of highly selective oncology drugs from bench to bedside.

KEY WORDS: Precision oncology, Drug development, Targeted therapy, Antibody-drug conjugates (ADCs), PROTACs, Preclinical models, Patient-derived organoids (PDOs), Phase I clinical trials, Adaptive master protocols, Computational oncology, Generative AI, Isomorphic Labs Drug Design Engine (IsoDDE).

ARTICLE DETAILS

Published On:
24 July 2026

Available on:
https://ijpbms.com/

INTRODUCTION

Historically, the clinical management of malignant neoplasms relied heavily on broad-spectrum cytotoxic agents designed to disrupt DNA replication and cellular division. While drugs such as alkylating agents, antimetabolites, and anthracyclines succeeded in inducing tumor regression, their therapeutic indices were severely limited. This narrow window resulted in profound systemic toxicities, including myelosuppression, cardiotoxicity, and neurotoxicity, and led to the selection of highly resistant, aggressive clonal populations. The dawn of the genomic era initiated a major transition toward precision oncology, driven by a deeper

understanding of the molecular driver mutations that sustain tumor survival, proliferation, and metastasis[1,2].

Despite the clinical success of early targeted agents, such as first-generation tyrosine kinase inhibitors and monoclonal antibodies, long-term therapeutic efficacy is consistently challenged by the evolution of both primary and acquired drug resistance. Tumor heterogeneity, both spatial and temporal, enables subclonal populations to survive selective pressure through secondary gatekeeper mutations or the activation of parallel bypass pathways [3,4].

To overcome these resistance mechanisms and mitigate systemic toxicities, the drug development pipeline has evolved into a highly sophisticated, multi-phase trajectory. Modern oncology drug development integrates structure-based drug design, advanced *in vitro* and *in vivo* preclinical validation models, phase-specific clinical evaluation utilizing adaptive and master protocol designs, and expedited regulatory pathways designed to accelerate the transition from bench to bedside. This report evaluates this developmental journey, illustrating how next-generation chemical modalities, translational models, innovative trial designs, and computational biology are shaping the modern therapeutic landscape.

2. PRECLINICAL RESEARCH: MECHANISM DISCOVERY AND TARGET IDENTIFICATION

2.1. Identification of Oncogenic Drivers

The modern precision oncology pipeline begins with the identification of specific genomic alterations that serve as clonal drivers of oncogenesis. Rather than treating tumors based solely on tissue histology, contemporary therapeutics target precise molecular aberrations. Epidermal growth factor receptor (EGFR) exon 20 insertion mutations represent a historically challenging target in non-small cell lung cancer (NSCLC) because the structural conformation of the mutated kinase pocket prevents traditional EGFR tyrosine kinase inhibitors (TKIs) from binding effectively, necessitating the development of highly specialized small molecules [5]. Similarly, the human epidermal growth factor receptor 2 (HER2) gene can harbor activating mutations in its tyrosine kinase domain (TKD) or undergo amplification, driving uncontrolled downstream signaling in lung, breast, and gastric malignancies [5].

In the space of intracellular signaling, the KRAS G12C mutation acts as a critical molecular switch that remains locked in an active, GTP-bound state, continuously stimulating the mitogen-activated protein kinase (MAPK) cascade[7]. Lastly, in hormone receptor-positive (HR+) breast cancers, prolonged exposure to aromatase inhibitors exerts selective pressure that enriches for recurrent mutations in the ligand-binding domain (LBD) of the estrogen receptor 1 (ESR1) gene[9]. These mutations, most frequently Y537S and D538G, stabilize the receptor in a constitutively active conformation, enabling ligand-independent transcriptional signaling and tumor proliferation even in the complete absence of estrogen[9]

2.2. Modality Screening and Rational Drug Design

The rational design of small-molecule kinase inhibitors utilizes high-resolution crystallography and computational modeling to optimize binding affinity and selectivity. Next-generation inhibitors are designed as either reversible or irreversible covalent agents. Reversible inhibitors rely on non-covalent interactions, such as hydrogen bonding and hydrophobic fit, designed to match the topology of mutated kinase pockets[5]. Irreversible inhibitors feature electrophilic warheads, such as acrylamide groups, that form a stable covalent bond with conserved cysteine residues near the ATP-binding pocket[8]. This covalent linkage ensures prolonged target engagement and sustained signaling inhibition, which is crucial for overcoming the rapid kinase turnover characteristic of mutated EGFR or HER2 driven tumors[5].

For extracellular and cell-surface targets, antibody-drug conjugates (ADCs) utilize a tripartite architecture to achieve selective intracellular delivery of highly potent cytotoxic payloads[10,12]. This structure comprises a highly specific monoclonal antibody, a chemical linker, and a cytotoxic payload[12,13]. The design is exemplified by datopotamab deruxtecan (Dato-DXd), which features a humanized IgG1 monoclonal antibody targeting Trophoblast cell-surface antigen-2 (TROP2) with a dissociation constant of K_D=0.74nM (Figure 1)[12]. The antibody is conjugated to DXd, a highly potent topoisomerase I inhibitor with an IC_{50}=0.31μmol/L , via an enzymatically cleavable tetrapeptide (GGFG) linker[12]. This linker exhibits high plasma stability, releasing only 1.4% to 5.5% of the payload in circulation after 21 days, minimizing systemic toxicity[12]. With a drug-to-antibody ratio (DAR) of 4:1, the ADC internalizes into target cells where lysosomal proteases cleave the GGFG linker, releasing the membrane-permeable DXd payload[12]. This release facilitates a strong "bystander effect," allowing the payload to diffuse out of the target cell to kill adjacent, antigen-negative tumor cells within heterogeneous microenvironments[12].

Targeted protein degradation (TPD) represents a paradigm shift from occupancy-driven inhibition to event-driven catalytic degradation[14]. Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules consisting of a target-binding warhead connected via a flexible chemical linker to an E3 ubiquitin ligase-recruiting ligand, recruiting either cereblon (CRBN) or von Hippel-Lindau (VHL)(Figure 1)[14]. The PROTAC molecule recruits the target protein and the E3 ligase into a ternary complex[15]. This proximity triggers the transfer of ubiquitin molecules from the E2-conjugating enzyme within the Cullin-RING ligase complex to accessible lysine residues on the target protein[14]. Once polyubiquitinated, the target is recognized and degraded by the 26S proteasome[14,16]. Because the PROTAC molecule

dissociates after target degradation, it acts catalytically, enabling a single drug molecule to destroy multiple copies of the target protein[14]. This mechanism is highly effective against constitutively active mutants, such as ESR1 LBD mutants, achieving over 90% reduction in estrogen receptor alpha (ERα) levels compared to the occupancy-dependent degradation of selective estrogen receptor degraders (SERDs)[9]



Figure 1. Targeted Therapeutic Modalities and Molecular Mechanisms in Precision Oncology.

*The schematic illustrates three major mechanism-driven paradigms:**Panel 1 (Small-Molecule Kinase Inhibitors):** Structural comparison between reversible non-covalent inhibitors (relying on spatial fit and hydrogen bonding) and irreversible covalent inhibitors featuring electrophilic warheads that bind to conserved cysteine residues (e.g., Cys797). **Panel 2 (Antibody-Drug Conjugates):** Architecture of datopotamab deruxtecan (Dato-DXd), showcasing the anti-TROP2 antibody, stable GGFG cleavable linker, and topoisomerase I inhibitor payload (DXd) that induces cell death and triggers a bystander effect. **Panel 3 (Targeted Protein Degradation):** Catalytic mechanism of PROTACs forming a transient ternary complex that recruits an E3 ligase (CRBN/VHL) to polyubiquitinate the target protein for 26S proteasome degradation.*

2.3. In Vitro and In Vivo Preclinical Validation

To improve the translatability of preclinical findings to human clinical trials, researchers are transitioning from traditional two-dimensional (2D) monolayer cell cultures to more complex three-dimensional (3D) models and *in vivo* systems[17,18]. Each validation platform offers distinct advantages and limitations regarding turnaround time, physiological relevance, and utility in pharmacokinetic (PK) and pharmacodynamic (PD) profiling (Table-1) [19].

Table 1. Comparative Analysis of In Vitro and In Vivo Preclinical Validation Platforms.

Preclinical Model	Structural Complexity & Physiological Relevance	Turnaround Time	High-Throughput Compatibility	PK/PD Evaluation Role	Key Limitations
2D Monolayers	Low; lacks 3D geometry, extracellular matrix (ECM) components, and stromal interactions[20].	Very rapid (<1 week)[21].	Excellent; ideal for screening large compound libraries[20].	Early diagnostic triaging; rapid cytotoxicity readouts (e.g., LDH release) and high-throughput cell viability assays[21].	Fails to replicate multicellular resistance, physical drug barriers, and immune cell signaling[20].

3D Spheroids	Moderate; captures basic cell-cell and cell-ECM interactions, creating nutrient and oxygen gradients[20].	2–3 weeks[21].	Moderate-to-high[20].	Real-time imaging of drug distribution, penetration kinetics, and multicellular therapeutic responses[21].	Lacks the self-organizing structural complexity and lineage differentiation of true organ tissue[21].
Patient-Derived Organoids (PDOs)	High; preserves original tissue architecture, genomic profile, and multicellular heterogeneity[20].	>3 weeks (resected tissues can establish in 2–3 weeks; drug screens completed in 4 weeks)[21].	Moderate; compatible with automated screening workflows[20].	Direct *ex vivo* functional testing; live microscopy to monitor cell dynamics (e.g., T-cell motility) and drug-induced apoptosis[20].	High cost, complex culture conditions, and lacks functional vasculature and integrated immune components unless co-cultured[20].
Patient-Derived Xenografts (PDXs)	Very High; preserves systemic tumor-host interactions, native stromal architecture, and tumor microenvironment (TME)[21].	Weeks to months[21].	Low[21].	In vivo validation of systemic PK/PD profiles; evaluates drug clearance, biodistribution, and TME-dependent imaging biomarkers[21].	Extremely slow; host mice are immunodeficient, and species-specific metabolic differences can lower clinical predictive accuracy[21].

This table outlines the structural complexity, chronological turnaround times, high-throughput compatibility, and precise roles in pharmacokinetic (PK) and pharmacodynamic (PD) evaluation across 2D monolayers, 3D spheroids, patient-derived organoids (PDOs), and patient-derived xenograft (PDX) mouse models.

While 2D monolayers remain valuable for early high-throughput screening of synthetic compound libraries, their complete lack of microenvironmental context restricts their predictive accuracy for complex drug behaviors and multicellular resistance mechanisms[21]. Transitioning to 3D spheroids and patient-derived organoids (PDOs) preserves the cellular heterogeneity, spatial architecture, and genetic stability of parent tumors, allowing for direct functional testing that correlates with clinical patient response[22,23]. For systemic PK/PD profiling, Patient-Derived Xenograft (PDX) mouse models serve as critical *in vivo* translational platforms (Table-1) [21]. These models enable the direct evaluation of therapeutic clearance rates, tissue biodistribution, and target engagement within an intact, physiologically relevant vascular and stromal environment[21,24].

3. CLINICAL TRIAL PHASES: TRANSLATING BENCH TO BEDSIDE

3.1. Phase I: Safety, Tolerability, and Pharmacokinetics

The primary objective of Phase I clinical trials in oncology is to characterize the safety, tolerability, dose-limiting toxicities (DLTs), and pharmacokinetic/pharmacodynamic profiles of an investigational drug to establish the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D)[25]. These trials represent the first exposure of human subjects to a novel compound, requiring rigorous design to balance patient safety with the clinical necessity of identifying a therapeutic dose[26].

Historically, the standard "3+3" algorithmic design has been the mainstay of Phase I dose escalation. In this design, cohorts of three patients are enrolled at a specified dose level (Table-2) [27]. If zero of three patients experience a DLT, the trial escalates to the next pre-defined dose[27]. If one of three patients experiences a DLT, an additional three patients are enrolled at that same dose level[27]. If at most one of six patients experiences a DLT, escalation continues; however, if two or more of three (or two or more of six) patients experience a DLT, escalation is halted, and the previous lower dose is generally defined as the MTD[25]. While simple to implement and requiring no prior sample size

calculations, the "3+3" design is rigid, escalates slowly, and frequently exposes many patients to sub-therapeutic, ineffective doses[27].

To address these limitations, modern oncology trials utilize innovative designs like the Accelerated Titration Design (ATD) and the modified Continual Reassessment Method (mCRM)[29]. The ATD accelerates the early stages of dose finding by enrolling single-patient cohorts (cohort size = 1) at the initial low-dose levels [25]. Dose escalation proceeds aggressively until a Grade 2 or greater drug-related toxicity is observed[25]. Once this toxicity threshold is crossed, the cohort size is expanded, and the trial reverts to a standard "3+3" escalation rule (Table-2) [25]. This hybrid approach significantly reduces the time spent at sub-therapeutic doses, making it highly efficient for trials with numerous dose levels[26].

In contrast, the mCRM is a model-based design that utilizes Bayesian probability[26]. It establishes a continuous mathematical model of the dose-toxicity curve, incorporating preclinical data as a starting point[26]. As each cohort completes evaluation, all accumulated safety data are used to update the model in real time, and the next cohort is assigned to the dose estimated to be closest to the target toxicity rate (typically set at 20% to 25%)(Table-2) [28]. Comparative analyses show that mCRM and ATD achieve significantly higher MTD-to-starting-dose ratios compared to the "3+3" design, allowing trials to reach therapeutic doses faster without increasing patient risk[29].

Table 2. Methodological Frameworks of Phase I Dose-Escalation Designs.

Dose Escalation Design	Cohort Size	Escalation / De-escalation Rules	MTD-to-Starting-Dose Ratio	Key Advantages	Key Limitations
Standard "3+3" Design	Fixed cohorts of 3 patients[27].	Algorithmic; escalates if 0/3 DLTs; expands to 6 if 1/3 DLTs; de-escalates and stops if ≥2/3 or ≥ 2/6 DLTs[25].	Low (typically around 9-fold)[29].	Extremely simple; requires no computational modeling or pre-specified sample size calculations[27].	Slow escalation; treats too many patients at sub-therapeutic, ineffective doses; lacks statistical flexibility[27].
Accelerated Titration (ATD)	Cohort size = 1 initially; expands to cohort size = 3 upon toxicity[25].	Aggressive initial escalation; reverts to "3+3" rules if a Grade 2 or greater drug-related toxicity is observed[25].	High (typically around 22-fold)[29].	Minimizes exposure to sub-therapeutic doses; ideal for trials exploring large numbers of dose levels[26].	Relies on cohort expansion back to traditional algorithms, introducing late-stage rigidity[25].
Modified CRM (mCRM)	Small cohorts (1 to 3 patients)[26].	Model-based; uses Bayesian updating to continuously estimate MTD based on all accumulated patient data[26].	Very High (typically around 30-fold)[29].	High accuracy in identifying the correct MTD; optimizes patient allocation closer to the target toxicity rate[28].	High complexity; requires real-time biostatistical support and predefined prior toxicity models[26].

A systematic matrix comparing the operational cohort sizes, algorithmic/model-based escalation and de-escalation rules, relative Maximum Tolerated Dose (MTD) ratios, and structural trade-offs of the traditional "3+3" design, Accelerated Titration Design (ATD), and modified Continual Reassessment Method (mCRM).

3.2. Phase II and Phase III: Efficacy and Confirmatory Testing

Once the safety profile and the RP2D are established, the investigational drug advances to Phase II trials, which evaluate preliminary anti-tumor activity in specific patient cohorts. These trials often rely on surrogate endpoints to identify early efficacy signals, such as the Objective Response Rate (ORR), representing the proportion of patients achieving a predefined reduction in tumor burden, and the

Duration of Response (DoR), which measures the time from the initial documented response to disease progression or death[6].

Drugs demonstrating a strong therapeutic signal in Phase II advance to Phase III confirmatory trials[31]. These trials are large, multicenter, randomized controlled trials (RCTs) designed to compare the investigational drug against the current standard of care (SoC)[31]. The primary endpoints of Phase III trials are direct measures of clinical benefit: Progression-Free Survival (PFS), which measures the time a patient lives without disease progression, and Overall Survival (OS), the gold-standard endpoint measuring the time from randomization to death from any cause[12].

3.3. Modern Innovation in Trial Designs

To maximize efficiency and adapt to the genetic heterogeneity of cancers, clinical development programs are shifting from traditional one-drug, one-disease trial structures to master protocols that evaluate multiple hypotheses concurrently under a single overarching operational infrastructure[30].

Basket trials evaluate a single targeted therapy across multiple distinct disease types (different histologies) that share a common molecular driver[30]. A landmark example is the VE-BASKET trial, which evaluated the BRAF inhibitor vemurafenib across multiple non-melanoma cancers harboring the BRAF V600E mutation[33,34]. This approach has paved the way for tissue-agnostic approvals, such as pembrolizumab for microsatellite instability-high (MSI-H) solid tumors and larotrectinib for NTRK fusion-positive cancers[31].

Umbrella trials focus on a single disease type but stratify patients into multiple treatment arms, matching each subgroup to a different targeted therapy based on their specific biomarker profile[30]. The BATTLE trial in NSCLC pioneered this model, assigning patients to specific targeted arms based on EGFR, KRAS, VEGF, and CCND1 biomarkers[35].

Platform trials feature highly flexible, multi-arm, ongoing master protocols that allow investigator teams to dynamically add promising new treatment arms or drop ineffective ones based on interim performance evaluations[30]. The STAMPEDE platform trial in prostate cancer exemplifies this flexibility, evaluating over eleven distinct interventions within a single continuous framework[35].

In parallel with innovative trial designs, the integration of machine learning and causal AI is accelerating clinical trials[36]. Natural language processing algorithms sift through electronic health records and genomic databases to optimize patient matching and biomarker stratification, reducing patient screening times by up to 34% and recruitment costs by 20%[37].

A major innovation is the development of synthetic control arms[37]. By leveraging advanced statistical modeling and machine learning, researchers combine historical clinical trial data and real-world data (RWD) to construct virtual control groups[38]. These synthetic cohorts are matched to the active treatment arm using high-dimensional propensity scores and AI-derived radiomics signatures[39]. This approach is particularly valuable for rare disease indications and molecularly defined sub-populations where patient recruitment is challenging, and enrolling patients in a standard placebo or ineffective control arm poses significant ethical concerns[38].

4. REGULATORY HURDLES AND FINAL MARKET APPROVAL

4.1. Expedited Regulatory Pathways

To accelerate patient access to life-saving therapies, regulatory agencies like the FDA have established expedited development and review pathways. Fast Track Designation facilitates the development and expedites the review of drugs designed to treat serious conditions and fill unmet medical needs, enabling frequent interactions with the FDA and rolling review of NDA sections[32]. Breakthrough Therapy Designation is granted to drugs with preliminary clinical evidence showing substantial improvement over existing therapies on at least one clinically significant endpoint, offering intensive FDA guidance and executive involvement[32]. Priority Review commits the FDA to taking action on an application within six months (compared to ten months under standard review)[32]. Accelerated Approval allows for the approval of a drug for a serious or life-threatening condition based on a surrogate endpoint (e.g., ORR or PFS) that is reasonably likely to predict clinical benefit, subject to the requirement that the sponsor conduct Phase IV confirmatory trials to verify clinical benefit (OS)[6].

4.2. Recent Case Studies of Market Approvals (2025–2026 Trends)

The maturation of next-generation oncology therapeutics has led to several landmark FDA approvals in 2025 and 2026. These approvals highlight a growing emphasis on precision targeting, novel drug modalities, and biomarker-guided therapy.

Table 3. Landmark Regulatory Market Approvals in Precision Oncology (2025–2026 Trends).

Approved Agent	Primary Target / Modality	Pivotal Clinical Trial(s) & Phase	Key Efficacy Outcomes & Endpoints	Clinical Context & Significance
Vepdegestrant	Estrogen Receptor	VERITAC-2; Phase	Median PFS was 5	First-ever approved

(Veppanu)	Alpha (ERα)[14]; Oral PROTAC[32].	III[32].	months for vepdegestrant vs. 2.1 months for fulvestrant (HR=0.57) in ESR1-mutants[9]	PROTAC; achieves >90% ERα reduction, overcoming ESR1 LBD-mutant resistance[14].
Giredestrant	Estrogen Receptor Alpha (ERα); Oral SERD[7][12].	lidERA Breast Cancer; Phase III[42].	Adjuvant ER+ breast cancer: reduced risk of invasive disease recurrence or death by 30% (HR=)[42].	First oral SERD with positive Phase III results in the curative, adjuvant early-stage setting[42].
Zenocutuzumab-zbco (Bizengri)	HER2 / HER3; Bispecific Antibody[32].	Phase I/II Registrational Trial[32].	Evaluated in 19 patients with NRG1+ cholangiocarcinoma ; achieved an ORR of 36.8% (DoR: 2.8-12.9 months)[32].	First drug approved for NRG1 fusion-positive advanced, unresectable, or metastatic cholangiocarcinoma [32].
Datopotamab deruxtecan-dlnk (Datroway)	TROP2; Antibody-Drug Conjugate[12].	TROPION-Breast02; Phase III[12].	First-line mTNBC: median PFS was 10.8 months vs. 5.6 months (HR=0.57); median OS was 23.7 months vs. 18.7 months ($HR =$)[12].	Approved for unresectable/metastatic TNBC; displays a highly favorable safety profile with low rates of severe neutropenia[12].
Sunvozertinib (Zegfrovy)	EGFR Exon 20 insertions; Small-molecule TKI [5].	WU-KONG1B; Phase II[5].	Demonstrated durable objective responses in locally advanced or metastatic NSCLC post-platinum chemotherapy[5].	Specifically designed to overcome steric hindrance in the mutated EGFR pocket[5].
Zongertinib (Hernexeos)	HER2 (ERBB2) TKD mutations; Small-molecule TKI[5].	Beamion LUNG-1; Phase I/II[5].	2025: Second-line accelerated approval[6]. 2026: Expanded first-line approval based on robust ORR in treatment-naïve patients[6].	Highly selective TKI designed to spare wild-type EGFR, minimizing off-target toxicities[5].
Teclistamab (Tecvayli)	CD3 / BCMA; Bispecific T-cell Engager[6].	Phase I/II registrational combination study[6].	Approved in combination with Darzalex Faspro for relapsed/refractory multiple myeloma[6].	Dual-targeting bispecific immunotherapy that activates host T cells to directly lyse BCMA-expressing myeloma cells[6].
Pivekimab sunirine-pvzy (Decnupaz)	CD123; Antibody-Drug Conjugate[32].	Pivotal registration study; Phase I/II[32].	Approved for the treatment of adults with blastic	CD123-targeted conjugate utilizing a potent alkylating

			plasmacytoid dendritic cell neoplasm (BPDCN)[32].	agent payload to treat an ultra-rare hematologic malignancy[32].
Relacorilant (Lifyorli)	Glucocorticoid Receptor; Small-molecule inhibitor[46].	Pivotal registration trial; Phase III[46].	Approved for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer[46].	Represents a major systemic advance for platinum-resistant gynecologic malignancies in combinations[8][6].
Optune Pax	Tumor Treating Fields; Medical Device[6].	Pivotal registration study; Phase III[6].	Approved for the local treatment of locally advanced pancreatic cancer[6].	Represents the first FDA-approved therapeutic device specific for pancreatic cancer in nearly three decades[6].

A comprehensive summary detailing the molecular target, pivotal trial phases, key efficacy outcomes (mPFS, OS, ORR, HR), and clinical significance of next-generation oncology agents, PROTACs, bispecific antibodies, ADCs, and devices approved in 2025 and 2026.

The FDA approvals of Datopotamab deruxtecan (Dato-DXd) and fam-trastuzumab deruxtecan (T-DXd) represent a significant maturation of the ADC platform[32]. Dato-DXd's approval in triple-negative breast cancer (TNBC) was supported by the Phase III TROPION-Breast02 trial, which demonstrated a median PFS benefit of 10.8 months compared to 5.6 months for physician's choice chemotherapy, as well as an overall survival extension to 23.7 months[12]. Importantly, Dato-DXd displays a highly favorable safety profile compared to earlier TROP2-targeted ADCs like sacituzumab govitecan, which are frequently associated with severe myelosuppression and neutropenia[12]. Grade 3 or greater adverse events occurred in only 21% of patients on Dato-DXd compared to 45% on chemotherapy in the TROPION-Breast01 trial, with the primary manageable toxicities being stomatitis, fatigue, and low rates of interstitial lung disease (ILD)[12]. Concurrently, the regulatory footprint of T-DXd expanded into early-stage breast cancer[32]. Based on the DESTINY-Breast11 and DESTINY-Breast05 trials, T-DXd was approved for neoadjuvant treatment of stage II/III HER2-positive breast cancer and as adjuvant therapy for patients with residual invasive disease following neoadjuvant therapy, bringing highly potent, target-directed cytotoxicity to curative-intent settings(Table-3)[32].

The approval of vepdegestrant (Veppanu) on May 1, 2026, marks the therapeutic validation of the PROTAC drug class[32]. This approval was based on the Phase III VERITAC-2 trial, where oral vepdegestrant (200 mg q.d. with food) demonstrated a 43% reduction in the risk of disease progression or death compared to fulvestrant (HR=0.57) in endocrine-resistant, ESR1-mutated advanced breast cancer[9] The clinical success of vepdegestrant highlights the superiority of catalytic protein degradation over traditional receptor antagonism, as vepdegestrant achieved a >90% reduction of ERα in preclinical models compared to approximately 60% for the oral SERD elacestrant and 50% for the intramuscular injection fulvestrant[14]. To support precise patient selection, the FDA approved the Guardant360 CDx as a liquid biopsy companion diagnostic, demonstrating high concordance in detecting baseline ESR1 hotspot mutations (Y537S and D538G) from circulating tumor DNA(Table-3)[14].

4.3. Phase IV: Post-Marketing Surveillance and Real-World Evidence (RWE)

Following market approval, therapeutics enter Phase IV post-marketing surveillance to monitor long-term safety, identify low-frequency toxicities, and evaluate efficacy across diverse real-world patient populations. Because registrational trials often employ strict inclusion and exclusion criteria, they may not fully capture the toxicity profiles of patients with significant comorbidities or organ impairment.

Real-world evidence (RWE) plays an increasingly critical role in this phase. For example, post-marketing analyses of oral SERDs (like elacestrant) in 2025 and 2026 confirmed the PFS benefits observed in the pivotal EMERALD trial, providing clinicians with additional confidence in the real-world utility of these oral regimens[40, 47]. RWE also monitors for late-onset, life-threatening toxicities, such as delayed interstitial lung disease (ILD) in patients receiving deruxtecan-based ADCs or cumulative cardiotoxicity associated with HER2-targeted agents, allowing for the refinement of clinical dosing guidelines and safety protocols.

5. CHALLENGES, FUTURE PERSPECTIVES, AND AI INTEGRATION

5.1. Mechanisms of Acquired Resistance

Despite the success of modern targeted therapies, tumors inevitably develop resistance under selective pressure, utilizing both "on-target" and "off-target" mechanisms. Secondary gatekeeper mutations directly interfere with drug binding[7]. A classic example is the EGFR C797S mutation, which arises in patients progressing on the third-generation EGFR TKI osimertinib[11,43]. The C797S mutation prevents osimertinib from forming its essential covalent bond with the EGFR kinase domain[11,44]. In the context of KRAS G12C inhibitors, secondary mutations like Y96D/C disrupt drug binding within the switch-II pocket, rendering sotorasib and adagrasib ineffective.[4]

In contrast, off-target resistance is frequently driven by bypass pathway activation[48]. When KRAS G12C is inhibited, the loss of downstream MAPK signaling halts negative feedback loops mediated by DUSP and SPRY genes[48]. This triggers an upstream rebound, upregulating growth factor receptors (such as EGFR, HER2, FGFR, and c-Met)[7]. These activated RTKs recruit the SHP2 phosphatase, activating wild-type NRAS and HRAS to restore downstream ERK and MAPK signaling[7]. This biology provides a clear rationale for combining KRAS G12C inhibitors with anti-EGFR antibodies (e.g., sotorasib plus panitumumab, or adagrasib plus cetuximab) to lock down parallel signaling loops simultaneously[41,49].

Lastly, cancers can escape therapeutic pressure by undergoing histological transdifferentiation. For instance, KRAS G12C-mutant lung adenocarcinomas can transdifferentiate into squamous cell carcinomas upon progression on adagrasib[7,50]. This transition is driven by chromatin remodeling and cell lineage plasticity, particularly in tumors harboring co-mutations in STK11/LKB1 or KEAP1, which reduce dependency on the original oncogene[7].

5.2. Biomarker-Driven Diagnostics and Liquid Biopsy

Liquid biopsy technologies have transformed longitudinal tumor surveillance by enabling non-invasive, serial analysis of circulating tumor DNA (ctDNA)[51]. Modern ctDNA platforms combine error-corrected next-generation sequencing (NGS) with epigenetic methylation and fragmentomic signatures, achieving analytical sensitivities below variant allele frequency[53].

Liquid biopsies are highly effective for early detection of Minimal Residual Disease (MRD)—the subclinical tumor burden that remains after curative-intent therapy and escapes standard radiographic imaging[52]. The clinical utility of MRD-guided therapy is highlighted by the May 15, 2026, FDA approval of atezolizumab for the adjuvant treatment of muscle-invasive bladder cancer (MIBC)[45]. Under this approval, atezolizumab is indicated exclusively for patients who are ctDNA MRD-positive post-cystectomy[45]. Rather than treating all patients based on anatomic staging, this molecular-guided approach ensures that immunotherapy is directed only to patients with confirmed molecular relapse, sparing MRD-negative patients from unnecessary systemic toxicity and clinical cost[45].

Additionally, serial ctDNA profiling can detect the emergence of acquired resistance mutations (such as ESR1 or EGFR mutations) a median of eight weeks before radiographic progression, enabling proactive treatment adjustments before clinical deterioration occurs[53].

5.3. Computational Oncology and Deep Learning

The integration of deep learning and generative AI has revolutionized the drug discovery pipeline, shifting the field from high-throughput empirical screening to rational computational drug design[54,55]. Traditional virtual screening relies on matching chemical libraries to static protein structures. Next-generation generative models, such as PCMol, leverage latent protein representations derived from AlphaFold2 to guide de novo drug design[56].

PCMol is designed as a transformer encoder-decoder model[56]. It extracts rich, structural protein representations from AlphaFold's Evoformer module (the m_{si} tensor) and the Structure module (the a_i tensor)[56]. Because AlphaFold's architecture is based on transformers, the size of these embeddings scales with sequence length (L), resulting in a raw tensor size of [384Xl][56]. PCMol reshapes these embeddings to a uniform vector shape [384x1] by averaging across the residue dimension, retaining structural family-specific clustering[56]. The model is trained with an autoregressive objective: it predicts the next chemical token of a molecule in SMILES string format while being conditioned on these target protein embeddings[56]. To align dimensions, the AlphaFold embeddings are projected through a fully connected layer to match the decoder's inner feature dimension (d=768)[56]. Using cross-attention mechanisms, the decoder translates the structural protein embeddings into the chemical space of active, target-specific compounds[56]. This conditioning enables target-side generalization, allowing the model to design novel, highly selective active ligands even for target proteins with sparse ligand data or completely held-out targets[56].

The Isomorphic Labs Drug Design Engine (IsoDDE) represents a significant advancement beyond AlphaFold 3, providing a unified in silico system for drug design[57]. While AlphaFold 3 predicted static structures, IsoDDE excels in modeling out-of-distribution biological systems, pocket dynamics, and physical interactions: **Novel System Generalization:** On the "Runs N' Poses" benchmark, IsoDDE more than doubles the structural prediction accuracy of AlphaFold 3 on the most challenging, out-of-distribution ligand-protein systems[57]. **Conformational Dynamics:** IsoDDE models complex biological mechanisms such as induced-fit adjustments and the opening of cryptic pockets (binding pockets that remain closed or hidden in the absence

of a ligand)[57]. For example, IsoDDE successfully predicted the structure of a protein-protein interaction inhibitor bound to a cryptic pocket at the NKG2D homo-dimer interface, a task where AlphaFold 3 failed (Figure 2)[57]. **Antibody-Antigen Modeling:** On a low-homology test set (n=334), IsoDDE outperforms AlphaFold 3 by 2.3- fold and Boltz-2 by 19.8-fold in predicting high-fidelity antibody-antigen complexes (defined by a DockQ score >0.8)[57]. It demonstrates high precision in modeling the hypervariable CDR-H3 loop, which is critical for de novo therapeutic antibody design[57]. **Binding Affinity Prediction:** IsoDDE predicts small-molecule binding affinities with accuracies exceeding gold-standard physics-based methods like free energy perturbation (FEP+) across benchmarks such as OpenFE and the CASP16 blind binding tasks, completed at a fraction of the time and cost (Figure 2)[57].



Figure 2. Deep Learning and Generative AI Architectures in De Novo Drug Discovery.

*The schematic illustrates the validation and processing pathways of computational oncology engines:**Left (PCMol Architecture):** Transformer encoder-decoder network that averages AlphaFold2 structural protein embeddings to condition an autoregressive decoder for target-specific compound generation in SMILES string format. **Right (IsoDDE Capabilities):** Performance benchmarks of the Isomorphic Labs Drug Design Engine demonstrating predictive validation in structural prediction accuracy (Runs N' Poses), cryptic pocket dynamics, high-fidelity antibody-antigen modeling (DockQ > 0.8), and blind binding affinity estimation relative to physics-based FEP+ methods.*

6. CONCLUSION

The convergence of fast-paced structural biology, targeted protein degradation, next-generation antibody-drug conjugates, and adaptive clinical trial designs has accelerated the clinical translation of oncology therapeutics. This paradigm shift is further accelerated by regulatory frameworks designed to bring highly effective, biomarker-guided therapies to patients with severe unmet needs.

Looking ahead, the clinical management of cancer is moving toward personalized immunotherapy and multi-targeted regimens:**Personalized Cancer Vaccines:** Rather than relying on generic immunotherapies, trials are evaluating personalized neoantigen mRNA vaccines[58]. These vaccines are custom-tailored to each patient's unique tumor mutational profile[59]. For example, in a Phase II trial of patients with high-risk stage III/IV melanoma, the combination of Moderna's mRNA-based personalized vaccine (intismeran autogene) with pembrolizumab halved the risk of recurrence or death over 60 months (hr=0.51) compared to pembrolizumab alone, showing the potential of vaccine-induced T-cell responses[60]. **Multi-Targeted "N-of-1" Regimens:** High-throughput functional genomics and real-world clinical trials, such as the I-PREDICT trial, are shifting the field away from the traditional "one mutation, one drug" model[61]. Because advanced malignancies are highly heterogeneous and driven by multiple genomic pathways, clinicians are designing highly customized multi-drug regimens[61]. The I-PREDICT trial demonstrated that when combination therapies are closely matched to a patient's specific genomic profile—often resulting in novel drug pairings that have never been tested together before—patients experience significantly prolonged PFS and OS without experiencing an increase in severe toxicities [61].

By combining computational drug design, longitudinal liquid biopsy monitoring, and adaptive clinical protocols, the

oncology field is establishing a new standard of care centered on highly personalized, dynamic, and multi-targeted therapeutic strategies.

REFERENCES

I. Falzone, Luca, Salvatore Salomone, and Massimo Libra. 2018. "Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium." *Frontiers in Pharmacology* 9 (1300). https://doi.org/10.3389/fphar.2018.01300.

II. Doroshow, Deborah B., and James H. Doroshow. 2019. "From the Broad Phase II Trial to Precision Oncology." The Cancer Journal 25 (4): 245–53. https://doi.org/10.1097/ppo.0000000000000386.

III. Lim, Zuan-Fu, and Patrick C. Ma. 2019. "Emerging Insights of Tumor Heterogeneity and Drug Resistance Mechanisms in Lung Cancer Targeted Therapy." Journal of Hematology & Oncology 12 (1). https://doi.org/10.1186/s13045-019-0818-2.

IV. Burrell, Rebecca A., and Charles Swanton. 2014. "Tumour Heterogeneity and the Evolution of Polyclonal Drug Resistance." Molecular Oncology 8 (6): 1095–1111. https://doi.org/10.1016/j.molonc.2014.06.005.

V. Tomić, Krešimir, and Semir Vranić. 2026. "A Remarkable Year for NSCLC: Seven New FDA Approvals in 2025 across Molecular Targets." Biomolecules and Biomedicine 26 (6): 869–71. https://doi.org/10.17305/bb.2026.13832.

VI. Cancer. 2026. "FDA Approvals in Oncology: January-March 2026." American Association for Cancer Research (AACR). April 2026. https://www.aacr.org/blog/2026/04/01/fda-approvals-in-oncology-january-march-2026/.

VII. Chour, Ali, Anne-Claire Toffart, Elodie Berton, and Michael Duruisseaux. 2024. "Mechanisms of Resistance to KRASG12C Inhibitors in KRASG12C-Mutated Non-Small Cell Lung Cancer." Frontiers in Oncology 14 (September). https://doi.org/10.3389/fonc.2024.1328728.

VIII. Blaquier, Juan Bautista, Andrés Felipe Cardona, and Gonzalo Recondo. 2021. "Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer." Frontiers in Oncology 11 (December). https://doi.org/10.3389/fonc.2021.787585.

IX. "Targeting ER Mutations and Drug Resistance - WuXi Biology." 2026. WuXi Biology. May 28, 2026. https://wuxibiology.com/?post_type=resource&p=9824.

X. Martinez, Thais, Samantha Wegner, and Hisham F. Bahmad. 2026. "ESR1 Mutations in ER-Positive Breast Cancer: From Endocrine Resistance to CtDNA-Guided Therapeutic Interception." Exploration of Targeted Anti-Tumor Therapy 7 (May). https://doi.org/10.37349/etat.2026.1002375.

XI. Wang, Zixi, Yurou Xing, Bingjie Li, Xiaoyu Li, Bin Liu, and Yongsheng Wang. 2022. "Molecular Pathways, Resistance Mechanisms and Targeted Interventions in Non-Small-Cell Lung Cancer." Molecular Biomedicine 3 (1). https://doi.org/10.1186/s43556-022-00107-x.

XII. Jiang, Kuikui, and Shusen Wang. 2026. "Advances in TROP2-Targeted Antibody-Drug Conjugates for Breast Cancer Therapy: Into the New Era." Cancer Biology & Medicine 23 (3): 327–37. https://doi.org/10.20892/j.issn.2095-3941.2025.0504.

XIII. "ADC Drugs by Target in 2026: 21 Approved ADCs List." 2026. DengYueMed. March 17, 2026. https://dengyuemed.com/blog/adc-drugs-by-target-in-2026/.

XIV. PatSnap. 2026. "ERα Degradation Efficiency: Vepdegestrant vs. Elacestrant vs. Fulvestrant in ESR1-Mutant Models." PatSnap. April 23, 2026. https://www.patsnap.com/resources/blog/ls-blog/vepdegestrant-protac-er-degrader-fda-filing-patsnap-eureka/.

XV. Bai, Nan, Sven A. Miller, Grigorii V. Andrianov, Max Yates, Palani Kirubakaran, and John Karanicolas. 2021. "Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta." Journal of Chemical Information and Modeling 61 (3): 1368–82. https://doi.org/10.1021/acs.jcim.0c01451.

XVI. Girardini, Miriam, Chiara Maniaci, Scott J. Hughes, Andrea Testa, and Alessio Ciulli. 2019. "Cereblon versus VHL: Hijacking E3 Ligases against Each Other Using PROTACs." Bioorganic & Medicinal Chemistry 27 (12): 2466–79. https://doi.org/10.1016/j.bmc.2019.02.048.

XVII. "Ternary Complex Formation." 2026. Promega.com. 2026. https://www.promega.com/applications/small-molecule-drug-discovery/protein-degradation-drug-discovery/e3-ternary-complex/.

XVIII. Wu, Kingsley Y, Ta I Hung, and Chia-en A Chang. 2024. "PROTAC-Induced Protein Functional Dynamics in Targeted Protein Degradation." BioRxiv (Cold Spring Harbor Laboratory), September. https://doi.org/10.7554/elife.101127.1.

XIX. Konstantinidou, Markella, Jingyao Li, Bidong Zhang, Zefeng Wang, Shabnam Shaabani, Frans Ter Brake, Khaled Essa, and Alexander Dömling. 2019. "PROTACs– a Game-Changing

Technology." Expert Opinion on Drug Discovery 14 (12): 1255–68. https://doi.org/10.1080/17460441.2019.1659242.

XX. Katya Mameishvili, Ph.D. 2025. "3D Organoids vs 2D Cell Lines in Drug Discovery and Disease Modeling." Biocompare.com. May 20, 2025. https://www.biocompare.com/Editorial-Articles/619144-3D-Organoids-vs-2D-Cell-Lines-in-Drug-Discovery-and-Disease-Modeling/.

XXI. Zhang, Yizheng, Naray Payab, Bettina Weigelin, and Christian M. Schürch. 2026. "From 2D Cultures to 3D Systems: Evolving Cancer Models at the Interface of Functional Precision Medicine and Theranostics." Theranostics 16 (8): 4042–57. https://doi.org/10.7150/thno.127053.

XXII. Suarez-Martinez, Elisa, Irene Suazo-Sanchez, Manuel Celis-Romero, and Amancio Carnero. 2022. "3D and Organoid Culture in Research: Physiology, Hereditary Genetic Diseases and Cancer." Cell & Bioscience 12 (April): 39. https://doi.org/10.1186/s13578-022-00775-w.

XXIII. Powley, Ian R., Meeta Patel, Gareth Miles, Howard Pringle, Lynne Howells, Anne Thomas, Catherine Kettleborough, et al. 2020. "Patient-Derived Explants (PDEs) as a Powerful Preclinical Platform for Anti-Cancer Drug and Biomarker Discovery." British Journal of Cancer 122 (6): 735–44. https://doi.org/10.1038/s41416-019-0672-6.

XXIV. Braun, Rüdiger, and Hendrik Ungefroren. 2023. "Preclinical Patient-Derived Culture Models for Personalized Treatment of Pancreatic Cancer: A Dream of the Future or Useful Practice?" Cancers 15 (11): 3027–27. https://doi.org/10.3390/cancers15113027.

XXV. Study Details | NCT05116709 | Assessment of Safety and Preliminary Clinical Efficacy with BAT6005 in Advanced Malignant Solid Tumors | ClinicalTrials.gov, accessed June 8, 2026, https://clinicaltrials.gov/study/NCT05116709

XXVI. Wei, Lai, Xueliang Pan, and Soledad Fernandez. 2019. "Practical Considerations for the Implementation of Adaptive Designs for Oncology Phase I Dose-Finding Trials." Future Drug Discovery 1 (2). https://doi.org/10.4155/fdd-2019-0021.

XXVII. Practical considerations for the implementation of adaptive designs for oncology Phase I dose-finding trials - PMC, accessed June 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC6811732/

XXVIII. Paoletti, X, M. Ezzalfani, and C. Le Tourneau. 2015. "Statistical Controversies in Clinical Research: Requiem for the 3 + 3 Design for Phase I Trials." Annals of Oncology 26 (9): 1808–12. https://doi.org/10.1093/annonc/mdv266.

XXIX. Le Tourneau, Christophe, Hui K. Gan, Albiruni R. A. Razak, and Xavier Paoletti. 2012. "Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents." PLoS ONE 7 (12). https://doi.org/10.1371/journal.pone.0051039.

XXX. Park, Jay J. H., Grace Hsu, Ellie G. Siden, Kristian Thorlund, and Edward J. Mills. 2020. "An Overview of Precision Oncology Basket and Umbrella Trials for Clinicians." CA: A Cancer Journal for Clinicians 70 (2): 125–37. https://doi.org/10.3322/caac.21600.

XXXI. Basket vs. Umbrella Trials: Master Protocols Explained - IntuitionLabs, accessed June 8, 2026, https://intuitionlabs.ai/articles/basket-vs-umbrella-trials

XXXII. May 2026: FDA Oncology Actions at a Glance | Targeted Oncology ..., accessed June 8, 2026, https://www.targetedonc.com/view/may-2026-fda-oncology-actions-at-a-glance

XXXIII. Park, Jay J. H, Ellie Siden, Michael J. Zoratti, Louis Dron, Ofir Harari, Joel Singer, Richard T. Lester, Kristian Thorlund, and Edward J. Mills. 2019. "Systematic Review of Basket Trials, Umbrella Trials, and Platform Trials: A Landscape Analysis of Master Protocols." Trials 20 (1). https://doi.org/10.1186/s13063-019-3664-1.

XXXIV. Basket trials in rare diseases: a systematic review of current practices, methodological challenges, and future directions - PMC, accessed June 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12613744/

XXXV. Evolving Trial Designs Advance Precision Medicine Through Basket, Umbrella, and Platform Models | Applied Clinical Trials Online, accessed June 8, 2026, https://www.appliedclinicaltrialsonline.com/view/evolving-trial-designs-advance-precision-medicine-basket-umbrella-platform-models

XXXVI. Kolla, Likhitha, Fred K Gruber, Omar Khalid, Colin Hill, and Ravi B Parikh. 2021. "The Case for AI-Driven Cancer Clinical Trials – the Efficacy Arm in Silico." Biochimica et Biophysica Acta - Reviews on Cancer 1876 (1): 188572–72. https://doi.org/10.1016/j.bbcan.2021.188572.

XXXVII. AI in Clinical Development Plans: Methods & Impact | IntuitionLabs, accessed June 8, 2026, https://intuitionlabs.ai/articles/ai-clinical-development-plans-trials

XXXVIII. Will synthetic control arms revolutionize clinical trials? - Servier, accessed June 8, 2026, https://servier.com/en/newsroom/synthetic-

control-arms-revolutionize-clinical-trials/

XXXIX. How can synthetic control arms transform clinical trials? We go into detail on the implementation of AI in disease detection - Quibim, accessed June 8, 2026, https://quibim.ai/news/synthetic-control-arm-in-clinical-studies/

XL. Jørgensen, Jan Trøst. 2026. "FDA 2025 Cancer Drug Approvals: Targeted Therapy Dominates." Exploration of Targeted Anti-Tumor Therapy 7 (April). https://doi.org/10.37349/etat.2026.1002369.

XLI. ADC Pipeline Update: Four Antibody-Drug Conjugates Designated in February 2026, accessed June 8, 2026, https://www.patsnap.com/resources/blog/articles/adc-pipeline-february-2026/

XLII. "Genentech: Press Releases | FDA Accepts New Drug Application for Genentech's Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD with Positive Phase III Results in the Curative Setting." 2026. Gene.com. 2026. https://www.gene.com/media/press-releases/15115/2026-06-01/fda-accepts-new-drug-application-for-gen.

XLIII. FDA accepts New Drug Application for Roche's giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting, accessed June 8, 2026, https://www.roche.com/media/releases/med-cor-2026-06-02

XLIV. Novel Drug Approvals for 2025 | FDA, accessed June 8, 2026, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025

XLV. Oncology (Cancer)/Hematologic Malignancies Approval Notifications - FDA, accessed June 8, 2026, https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications

XLVI. Novel Drug Approvals for 2026 - FDA, accessed June 8, 2026, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

XLVII. Breast Cancer Breakthroughs Episode 21: Real World Impact of Oral SERDs, accessed June 8, 2026, https://www.komen.org/blog/bcbt-real-world-impact-oral-serds/

XLVIII. Akhave, Neal S., Amadeo B. Biter, and David S. Hong. 2021. "Mechanisms of Resistance to KRASG12C-Targeted Therapy." Cancer Discovery 11 (6): 1345–52. https://doi.org/10.1158/2159-8290.cd-20-1616.

XLIX. FDA-Approved Oncology Therapies - OncoKB, accessed June 8, 2026, https://www.oncokb.org/oncology-therapies

L. Tanaka, Noritaka, and Hiromichi Ebi. 2024. "Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt." Cancer Science, December. https://doi.org/10.1111/cas.16441.

LI. Li, Yiyang, Zixuan Liu, Benliang Yuan, Tianshuai Zhang, Xiaoming Zhu, Leqi Zhou, Wei Zhang, and Guanyu Yu. 2026. "Liquid Biopsy in Cancer Drug Resistance: Real-Time Monitoring, Mechanistic Insights, and Translational Applications." Frontiers in Immunology 17 (April). https://doi.org/10.3389/fimmu.2026.1795789.

LII. Fang, Xiaoxu, Shaokun Yu, Yingying Jiang, Yan Xiang, and Kaihua Lu. 2022. "Circulating Tumor DNA Detection in MRD Assessment and Diagnosis and Treatment of Non-Small Cell Lung Cancer." Frontiers in Oncology 12: 1027664. https://doi.org/10.3389/fonc.2022.1027664.

LIII. Gianna Di Sario, Valeria Rossella, Elvira Smeralda Famulari, Aurora Maurizio, Dejan Lazarević, Francesca Giannese, and Claudia Felici. 2023. "Enhancing Clinical Potential of Liquid Biopsy through a Multi-Omic Approach: A Systematic Review." Frontiers in Genetics 14 (April). https://doi.org/10.3389/fgene.2023.1152470.

LIV. Circulating Tumor DNA (ctDNA) Testing to Predict Response in Solid Tumors, accessed June 8, 2026, https://www.pharmacytimes.com/view/circulating-circulating-tumor-dna-ctdna-testing-to-predict-response-in-solid-tumorstumor-dna-ctdna-testing-to-predict-response-in-solid-tumors

LV. Integrating AlphaFold into the Drug Discovery Process - Creative Biostructure, accessed June 8, 2026, https://www.creative-biostructure.com/integrating-alphafold-drug-discovery.htm

LVI. AlphaFold Meets De Novo Drug Design: Leveraging Structural ..., accessed June 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11558674/

LVII. The Isomorphic Labs Drug Design Engine unlocks a new frontier ..., accessed June 8, 2026, https://www.isomorphiclabs.com/articles/the-isomorphic-labs-drug-design-engine-unlocks-a-new-frontier

LVIII. Fayyaz, Amna, Aleena Haqqi, Rashid Khan, Muhammad Irfan, Khushbukhat Khan, Željko Reiner, Javad Sharifi-Rad, and Daniela Calina. 2024. "Revolutionizing Cancer Treatment: The Rise of Personalized Immunotherapies." Discover Oncology 15 (1). https://doi.org/10.1007/s12672-

024-01638-1.

LIX. Fnu Rukhayya, Lahari Katta, Hana Khan Ghori, Shreya Kattela, Maahin Parvez, Sarojini Posani, Mihirkumar P Parmar, Fnu Jatin, Sweta Sahu, and Salma Younas. 2025. "Personalized Cancer Vaccines in Combination Therapies: Current Status and Future Prospects." Asian Pacific Journal of Cancer Prevention 26 (8): 2741–54. https://doi.org/10.31557/apjcp.2025.26.8.2741.

LX. Stefano Zoroddu, and Luigi Bagella. 2025. "Next-Generation MRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies." Cells 14 (18): 1476–76. https://doi.org/10.3390/cells14181476.

LXI. Debela, Dejene Tolossa, Seke GY Muzazu, Kidist Digamo Heraro, Maureen Tayamika Ndalama, Betelhiem Woldemedhin Mesele, Dagimawi Chilot Haile, Sophia Khalayi Kitui, and Tsegahun Manyazewal. 2021. "New Approaches and Procedures for Cancer Treatment: Current Perspectives." SAGE Open Medicine 9 (9): 205031212110343. https://doi.org/10.1177/20503121211034366.